Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3363812 | 0.99 | TLR7 (0.67) | TLR7IL6 | |
| Hydrochloric Acid SCHEMBL3360874 | 0.99 | TLR7 (0.67) | TLR7IL6 | |
| SCHEMBL2390244 | 0.99 | TLR7 (0.68) | TLR7IL6 | |
| SCHEMBL2843218 | 0.98 | TLR7 (0.65) | TLR7IL6 | |
| SCHEMBL2389795 | 0.96 | TLR7 (0.66) | TLR7IL6 | |
| SCHEMBL4131529 | 0.94 | TLR7 (0.66) | TLR7 | |
| SCHEMBL4132555 | 0.94 | TLR7 (0.63) | TLR7IL6 | |
| SCHEMBL4135514 | 0.93 | TLR7 (0.60) | TLR7IL6 | |
| Azd-8848 SCHEMBL12047493 | 0.93 | TLR7 (0.66) | TLR7 | |
| Azd-8848 SCHEMBL29454274 | 0.93 | TLR7 (0.66) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135590-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | Janssen Science Ireland Unlimited Company (IE) | 2022-05-05 | — | — | US | claimed |
| EP-3976619-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | claimed |
| WO-2021023662-A1 | PYRAZOLO[4,3-C]PYRIDINE COMPOUNDS FOR USE IN THE TREATMENT OF HBV INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2021-02-11 | — | — | WO | claimed |
| WO-2020239863-A1 | DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | claimed |
| WO-2020239864-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | claimed |
| WO-2020239862-A1 | DI-FLUORO AZEPANES AS HBV CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | claimed |
| EP-3728272-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-10-28 | — | — | EP | claimed |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2020-07-14 | — | — | US | claimed |
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3312160-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | claimed |
| EP-1728793-B1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-03 | — | — | EP | claimed |
| US-9169212-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2015-10-27 | — | — | US | claimed |
| US-20150259324-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2015-09-17 | — | — | US | claimed |
| US-8969362-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2015-03-03 | — | — | US | claimed |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-02-13 | — | — | US | claimed |
| US-8575180-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2013-11-05 | — | — | US | claimed |
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG (SE) | 2011-12-15 | — | — | US | claimed |
| US-20110294802-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF METHYL (3-{ [[3-(6- AMINO- 2-BUTOXY-8-OXO-7, 8-DIHYDRO-9H-PURIN-9-YL) PROPYL] (3- MORPHOLIN-4-YLPROPYL) AMINO] METHYL }PHENYL) ACETATE AND THEIR USE IN THERAPY | DAINIPPON SUMITOMO PHARMA CO. LTD (JP) | 2011-12-01 | — | — | US | claimed |
| EP-2235018-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF METHYL (3-{ ÝÝ3-(6- AMINO- 2-BUTOXY-8-OXO-7, 8-DIHYDRO-9H-PURIN-9-YL) PROPYL¨(3- MORPHOLIN-4-YLPROPYL) AMINO¨METHYL }PHENYL) ACETATE AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | claimed |
| WO-2009078798-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF METHYL (3-{ [[3-(6- AMINO- 2-BUTOXY-8-OXO-7, 8-DIHYDRO-9H-PURIN-9-YL) PROPYL] (3- MORPHOLIN-4-YLPROPYL) AMINO] METHYL }PHENYL) ACETATE AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | IFNAR1, IL5, IFNG | TLR7 8/4885IL6 833/4885 |
| US-20220135590-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | HAVCR2, XDH, PYGL | TLR7 842/4885IL6 2430/4885 |
| US-20110294802-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF METHYL (3-{ [[3-(6- AMINO- 2-BUTOXY-8-OXO-7, 8-DIHYDRO-9H-PURIN-9-YL) PROPYL] (3- MORPHOLIN-4-YLPROPYL) AMINO] METHYL }PHENYL) ACETATE AND THEIR USE IN THERAPY | SLC10A1, HTR7, PURB | TLR7 79/4885IL6 217/4885 |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | IFNAR1, IL5, IFNG | TLR7 13/4885IL6 1009/4885 |
| US-20150259324-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | TLR7 620/4885IL6 1022/4885 |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | TLR7 757/4885IL6 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.